Maintaining Options for Mothers Study (MOMS): A phase II randomized comparison of three antiretroviral strategies administered for 7 or 21 days to reduce the emergence of nevirapine resistant HIV-1 following a single intrapartum dose of nevirapine.

Trial Profile

Maintaining Options for Mothers Study (MOMS): A phase II randomized comparison of three antiretroviral strategies administered for 7 or 21 days to reduce the emergence of nevirapine resistant HIV-1 following a single intrapartum dose of nevirapine.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nevirapine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MOMS
  • Most Recent Events

    • 08 Jan 2013 Results published in Clinical Infectious Diseases.
    • 18 Jan 2012 Actual patient number (484) added as reported by ClinicalTrials.gov.
    • 18 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top